Dare Bioscience, Inc. · NASDAQ:DARE
Dare Bioscience — Investor Presentation (July 2026)
39 slides from Dare Bioscience's investor presentation, Jul 13, 2026
Slide 1: Daré Bioscience
Wy DARE BIOSCIENCE
Slide 2: Forward-Looking Statements & Disclaimers
antscrooet 1) Forward-Looking Statements & Disclaimers This presentation is for informational purposes only and is not an offer to sel ora solicitation ofan offer to buy any securities of Daré Bioscience, Inc. ("Daré" or the "Company’). This presentation discusses potential future drug and ‘medical
Slide 3: Dare to Push Women's Health Forward
DAREBIOSCENCE DARE TO PUSH WOMEN'S HEALTH FORWARD Bioscience that’s 100% for her. La \ WN 0)
Slide 4: Investment Highlights
i) Investment Highlights xclusive Focus on Women's Health Purpose-built portfolio addressing large, underserved markets across women’s health. Commercial Launch & Development-Driven Growth Strategy Revenue commencing from product sales in 2026 with Advancing diversified pipeline of late- and mid-sta
Slide 5: Daré for Her at Every Stage of Life
DAREBICSCENCE io) Dare for Her at Every Stage of Life PLAY SUPPORT RECLAIM FIGHT Confidence and freedom Empowering your choices Care that supports you and _—_ Solutions to help you feel_ Innovations to help you thrive to live life your way. for today and tomorrow, the life you're building. like your
Slide 6: Pipeline Focused on Supporting Every Woman at Every Stage
antwcicovee i» Pipeline Focused on Supporting Every Woman at Every Stage Women's health is not a single condition. It is a lifelong healthcare journey affecting every woman, at every stage of life. >] Designed to maintain a Designed for her healthy vaginal microbiome sexual experience Flora Sync LF5
Slide 7: Why Women's Health
DAREBIOSCENCE Why Women's Health. D mo A ed es 5 | ~ L ‘SEXUAL HEALTH® MENOPAUSE” That is Not a Niche. That is a Significant Market Opportunity. ~70 million ~5 il million U.S. women experience some form U.S. women experience of sexual dysfunction, including low menopausal symptoms that of Q of desir
Slide 8: Significant Non-Dilutive Funding From Leading Institutions
AREBIOSCENCE io) Significant Non-Dilutive Funding From Leading Institutions Over $75 Million Awarded to Date Validates Approach and Need Gates Foundation ARPA-H NIH/ NICHD Committed $2.5 billion through Sprint for Women’s Health NIH-wide initiative to advance 2030 to advance women's health investing
Slide 9: Data Driven Development. Not Just Another Online Compounder.
antwcicovee i» Data Driven Development. Not Just Another Online Compounder. Built on Science, Clinical Evidence, FDA Development and Product Quality 01 02 G2) 03 (f Clinical Development Proprietary Products Commercial Platform Conducting clinical studies Oo KtarclGaaisterpendl + DARE Health Hub . 7
Slide 10: A Commercial Company with a Purpose-Built Women's Health Product Ecosystem
DAREBIOSCENCE D ACommercial Company with a Purpose-Built Women's Health @ Product Ecosystem
Slide 11: Flora Sync LF5
DAREBIOSCENCE DARE TO RESTORE™ Flora Sync LF5™ Non-hormonal probiotic vaginal capsule designed to restore microbiome balance and support lasting comfort —— = ans = Launched June 2026 @) Available without a prescription (>) Vaginal capsule formulated with Limosilactobacillus A a) fermentum LF5 Clinic
Slide 12: Sildenafil Cream
DAREIOSCENCE D DARE TO PLAY™ Sildenafil Cream* Proprietary topical formulation of the active 7 ingredient in an erectile dysfunction drug (Viagra®) + Prescriptions Dispensing Targeted Summer 2026 Prescribers Already Writing and Patients Engaging (2) No FDA-approved treatments for female sexual arous
Slide 13: Turning Clinical Relationships Into Commercial Momentum
antwcicoves i» Turing Clinical Relationships Into Commercial Momentum Years of product development have created trusted relationships with the providers most likely to adopt new women's health solutions Clinical Relationships @ a Built Through Development (Commoner Aa erty a Long-standing engagement
Slide 14: Integrated Commercial Platform Designed for Scalable Growth
antwcicovee > Integrated Commercial Platform Designed for Scalable Growth Driving patient acquisition, engagement, and portfolio expansion through a unified women's health ecosystem Provider Relationships + OBGYN and women's health a Va ON Digital Marketing specialist engagement © : © | =) + Consume
Slide 15: DARE Health Hub: Direct-to-Patient Growth Engine
DAREBIOSCENCE DARE Health Hub: Direct-to-Patient Growth Engine Central Commercial Platform Product education Qs Telehealth access Prescription fulfillment £2 Patient engagement Ae] Product cross-selling i) DARE nessrn wu Welcome to the DARE Health Hub Products bit by biotech,
Slide 16: Development
DAREBIOSCENCE Development acu Robust dev: aad ai halite. pede ontin to fuel commercial product portfolio
Slide 17: Ovaprene: Hormone-Free Monthly Intravaginal Contraceptive
DARE toPLAN™ Ovaprene: Investigational Hormone-Free Monthly Intravaginal Contraceptive Ongoing Phase 3 Study with Topline Data Expected 20271 Hormone-Free: Unique dual action MOA (spermiostatic & barrier), no hormonal safety concerns ( gO ) | 86% - 91% expected typical use effectiveness?? | ) | Conv
Slide 18: DARE-HPV
DAREBIOSCENCE DAREtoFIGHT™ DARE-HPV* Investigational Antiviral Vaginal Insert For Persistent High-Risk HPV Infection + Phase 2 Study Commenced May 20261 A proprietary fixed-dose formulation of lopinavir and ritonavir? in a soft gel vaginal insert (2) | Majority of women achieved no dysplasia and und
Slide 19: DARE-HRT1: Monthly Hormone Therapy for Menopause
DAREBIOSCENCE DARE toRECLAIM™ DARE-HRTI” Monthly Hormone Therapy for Menopause és 503B Compounding and Phase 3-Enabling Activities Underway A proprietary intravaginal ring designed to continuously deliver bio-identical estradiol and progesterone over 28 days Statistically significant improvements in
Slide 20: DARE-VVA1
DAREBIOSCENCE DAREto RECLAIM™ DARE-VVAI* Investigational Vaginal Insert for Genitourinary Syndrome of Menopause (GSM) + Phase 2 Study Preparations Underway A proprietary hormone-free vaginal insert containing tamoxifen for sexual pain post-menopause or breast cancer treatment. Statistically signific
Slide 21: DARE-FRT1/DARE-PTB1
DAREBIOSCENCE DARE to SUPPORT™ DARE-FRT1/DARE-PTB1 Investigational Sustained-Release Progesterone Intravaginal Ring for Pregnancy Maintenance Phase 1 Study Preparation Underway A proprietary intravaginal ring designed to deliver bio-identical progesterone as an alternative to daily injections or vag
Slide 22: Pipeline Expansion Opportunities from Earlier Stage Programs
DARESOSCIENCE Multiple Pipeline Expansion Opportunities from Earlier Stage Programs” ESTIMATED ADDRESSABLE PHASE 3/ Program MARKET PRE-CLINICAL PHASE 1 PHASE 2 PIVOTAL, Australia RED —yare.ppyy~ VaGina dilotenac once-dalythermoseting _So%menstuatng women Phase 1 study completed 2023 Cash Rebate hydr
Slide 23: Corporate Overview
DAREBIOSCENCE Corporate Overview
Slide 24: Financial Snapshot
DARERIOSCENCE D Nasdag: DARE Financial Snapshot Start of Product Revenue Generation with Commercial Launch of * Flora Sync LF5 in June 2026 and Upcoming Launch of DARE to PLAY in Summer 2026 + We) “a all AR ~$18.5M + ~$31M * 644K + ~15M Cash’ Market Cap Trading Volume Shares As of March 31, 2026 As
Slide 25: Management Team
maeecrs D Management Team i x Sabrina Martucci Johnson David Friend, PhD MarDee Haring-Layton Jessica Hatheway Annie Thurman, MD, FACOG Mark Walters CEO & President Chief Scientific Officer Chief Accounting Officer VP, Clinical Operations Medical Director VP, Operations a Robert Charboneau Jennifer
Slide 26: Multiple Near-Term Catalysts
nates 0) Multiple Near-Term Catalysts with Potential for Meaningful Value Creation PRODUCT | PROGRAM GRANT-FUNDED INFLECTION EVENT TIMING* VALUE CREATION Revenue; real-world data; estimated 20 milion U DARE to PLAY? Prescription dispensing; product revenue underserved women? with no FDA-approved tre
Slide 27: Why Daré, Why Now
Why Daré, Why Now. Transitioning to a Commercial-Stage Company with Two Revenue-Generating Products Launching and a Purpose- Built Development Pipeline Advancing to Support Women at Every Stage of Life Scalable Commercial Engine in Place DARE Health Hub, telehealth infrastructure, and provider relat
Slide 28: Daring to Put Her Health First
WD) ING Daring to Put Her Health First™ DDAREBIOSCIENCE COM | NASDAG: DARE (0026 DARE BIOSCIENCE. ALL RIGHTS RESERVED
Slide 29: DDARESIOSCIENCE.COM|
DDARESIOSCIENCE.COM| NASDAQ: DARE
Slide 30: FDA Approved Product: XACIATO
DAREBIOSCENCE FDA APPROVED PRODUCT: XACIATO™ (Clindamycin Phosphate) Vaginal Gel 2% ERODUCTINES) XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel 2% is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis (BV) in females 12 years of age and older* + Available na
Slide 31: XACIATO Selected Safety Information
DAREBIOSCENCE XACIATO™ (Clindamycin Phosphate) Vaginal Gel 2% SELECTEDSAFETY INFORMATION XACIATO is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin. Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacteri
Slide 32: Oral Sildenafil Provided Proof of Concept for FSAD
DAREBIOSCENCE Oral Sildenafil provided a compelling proof of concept for FSAD STATISTICALLY SIGNIFICANT INCREASES STATISTICALLY SIGNIFICANT IMPROVEMENT IN VAGINAL PULSE AMPLITUBE (VPA)' IN GENITAL STIMULATION (FIEI)? + Question #2. “After taking study medication, the Pfizer VPA Clinical Lab Study —
Slide 33: Path Forward for Sildenafil Cream for Treatment of FSAD
DAREBIOSCENCE Path Forward for Sildenafil Cream for Treatment of FSAD EXPLORATORY PHASE 2B CLINICAL STUDY' + The Phase 2b Clinical Study (ID# NCT04948151) was designed to evaluate Sildenafil Cream vs. placebo over 12 weeks. + To Daré’s knowledge, this was the first study specifically evaluating a po
Slide 34: Sildenafil Cream Phase 2b in FSAD: Post-Hoc Analyses
DaREaIosc: Sildenafil Cream Phase 2b in FSAD EXPLORATORY POST-HOC ANALYSES* 0) Post-Hoc Analysis Results from Proposed Phase 3 population: FSAD with or without concomitant decreased desire Sildenafil Cream + Post-hoc analyses were conducted on enrollment female sexual 3.6% (N=33) dysfunction diagnos
Slide 35: Sildenafil Cream Phase 2b in FSAD: Safety Results
DAREBIOSCENCE i» Sildenafil Cream Phase 2b in FSAD SUMMARY OF SAFETY RESULTS Sildenafil Cream was well tolerated by exposed users and their sexual partners. During the 12-week double-blind dosing period, there were 78 TEAEs reported by 29 of the 99 Sildenafil Cream-assigned participants and 65 TEAEs
Slide 36: Sildenafil Cream Pharmacokinetic and Pharmacodynamic Studies
DAREBIOSCENCE Sildenafil Cream, 3.6% Pharmacokinetic and Pharmacodynamic Studies PHASE 1 & PHASE 2A STUDY RESULTS Phase 1 Study of SST-6007 (Sildenafil Cream, 3.6%)" Normal healthy postmenopausal women (n=20) were dosed with escalating doses of Sildenafil Cream, 3.6%, using a cross-over study design
Slide 37: Notable Publications for Daré's Sildenafil Cream
DAREBIOSCENCE Notable Publications for Daré’s Sildenafil Cream, 3.6% PUBLICATION Sexual Medicine, Volume 12, Issue 5, October 2024 Obstetrics & Gynecology. 144(2):p 144-152, August 2024. The Journal of Sexual Medicine. 2024 Sep 3:21(9):793-799. The Journal of Sexual Medicine. 2024 Jul 26; 21(9): 787
Slide 38: Ovaprene Pre-Pivotal Postcoital Test
DAREBIOSCENCE OVAPRENE® Investigational Hormone-Free Monthly Intravaginal Contraceptive PREPNOTAL The Ovaprene® Pre-Pivotal Postcoital Test (PCT) ane study met its primary endpoint. + In 100% of women and cycles, Ovaprene prevented the requisite number of sperm from reaching the cervix. + Assuccessf
Slide 39: Ovaprene Regulatory Strategy and Pivotal Study Design
DAREBIOSCENCE OVAPRENE® Investigational Hormone-Free Monthly Intravaginal Contraceptive us. Based on our communications to date with the FDA, if successful, we REGULATORY ‘STRATEGY! believe only this single ongoing registration study will be sufficient to support a premarket approval application sub